Citations

Clear

2960 citation(s) found for "Kim, P".

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer
Flamand, Yael , Quon, Harry , Weinstein, Gregory S., Mehra, Ranee , Garcia, Joaquin J., Kim, Seungwon , O’Malley, Bert W. , Özer, Enver , Ikpeazu, Chukwuemeka , Koch, Wayne M. , Lango, Miriam N. , Smith, Russell K., Karakla, Daniel W., Richmon, Jeremy D. , Burtness, Barbara , Flamand, Yael , Quon, Harry , Mehra, Ranee , Ikpeazu, Chukwuemeka , Gross, Neil D , Bell, R Bryan , Lango, Miriam , Morris, Luc G T , Holsinger, F Chris , Ferris, Robert L , Richmon, Jeremy D , Burtness, Barbara , Garcia, Joaquin J., Bell, R. Bryan , Patel, Mihir R , Holsinger, F. Christopher , Ferris, Robert L.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2025 | Volume: 43 | Issue: 23 | Pages: 2559-2565

10.1200/jco-24-02550 | PMID 40493877 Get It

This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Cancer (AJCC) seventh edition p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (arm A); those with clear margins, 2-4 + LN, or ENE ≤1 mm were randomly assigned to 50 Gy (arm B) or 60 Gy (arm C); and those with involved margins, >4 + LN, or >1 mm ENE received weekly cisplatin and 60-66 Gy (arm D). Among 359 evaluable patients, the 54-month progression-free (PFS) and overall survival (OS) were 90.6% (90% CI, 87.2% to 93.1%) and 95.3% (93.0% to 96.9%), respectively. The 54-month PFS by arm was A 93.2% (79.6% to 97.8%; all four recurrences among N1 patients), B 94.9% (89.7% to 97.5%), C 90.2% (82.7% to 94.6%), and D 85.5% (77.5% to 90.8%). The 54-month OS by arm was A 97.1% (85.7% to 99.4%), B 97.9% (93.5% to 99.3%), C 95.1% (90.1% to 97.6%), and D 92.5% (86.9% to 95.7%). PFS or OS did not differ by primary site or smoking history. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS. Among patients with favorable pathologic characteristics, those with N1 disease are at risk of late recurrence without radiation.
Spouse and Child Caregivers’ Experiences of Lucid Episodes in Dementia: A Mixed Methods Approach
Kim, Kyungmin , Bangerter, Lauren R. , Liu, Yin , Finnie, Dawn M., Gaugler, Joseph E. , Griffin, Joan M. , Gaugler, Joseph E , Griffin, Joan M , Lapid, Maria I. , Kim, Kyungmin

Mayo Clinic

Innovation in Aging | June 10, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/geroni/igaf036 | PMID 40502729 Get It

Abstract Background and Objectives Lucid episodes (LEs) in people living with late-stage dementia have been reported anecdotally. However, how this seemingly unexpected phenomenon is experienced by family caregivers is less known. Focusing on the two most common groups of informal caregivers, spouses and adult children, this study examined variability in family caregivers’ experiences with LEs—whether they exhibit differential appraisals of and responses to LEs. Research Design and Methods Using a sample of former/bereaved and current family caregivers from UsAgainstAlzheimer’s A-LIST, we conducted an online survey of spouse and child caregivers (N = 387). We conducted semistructured interviews among a subset of caregivers who witnessed a LE (n = 22). Results Overall, child caregivers were more likely to witness a LE than spouse caregivers. Among former/bereaved caregivers who witnessed a LE (n = 139), spouses were likely to report nonverbal communication during LEs, appraise LEs more negatively, and make changes in care decisions, such as end-of-life planning and financial decisions, compared to adult children. Among current caregivers who witnessed a LE (n = 80), spouses often reported no special circumstances preceding LEs, whereas children linked LEs to friend/family visits. No significant differences were found in positive and negative appraisals of LEs between current spouse and child caregivers. Content analysis of qualitative interviews revealed the contexts underlying these differences. Discussion and Implications Differences between spouses and adult children in their experiences with LEs are related to their different caregiving contexts, including relationship history, living arrangements, expectations, motivations, and caregiving resources.
Hurting More Than Helping? Decompressive Craniectomy in Patients With Symptomatic Intracerebral Hemorrhage After Mechanical Thrombectomy in Acute Ischemic Stroke: Insights From Stroke Thrombectomy and Aneurysm Registry
Pressman, Elliot , Vakharia, Kunal , Guerrero, Waldo R. , Maier, Ilko , Raai, Ansaar, Jabbour, Pascal , Kim, Joon-Tae , Grossberg, Jonathan A , Wolfe, Stacey Q , Stark, Robert M., Psychogios, Marios‐Nikos , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Moss, Mark, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Mokin, Maxim, STAR, on behalf of, Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Ogilvy, Christopher S , Sowlat, Mohammad‐Mahdi , Schimmel, Samantha J. , Jabbour, Pascal , Alawieh, Ali , Stark, Robert M., Samaniego, Edgar A , Goyal, Nitin , Fiorella, David , Romano, Daniele G., Navía, Pedro , Cuellar, Hugo, Fragata, Isabel , Mascitelli, Justin R , Osbun, Joshua W , Limaye, Kaustubh , Matouk, Charles , Park, Min S. , Levitt, Michael R. , Gory, Benjamin , Grandhi, Ramesh , Paul, Alexandra R , Mokin, Maxim , STAR, on behalf of

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 2 | Pages: 345-357

10.1227/neu.0000000000003563 | PMID 40488514 Get It

BACKGROUND AND OBJECTIVES: It remains unclear whether decompressive craniectomy (DC) is beneficial in patients who suffer symptomatic intracerebral hemorrhage (sICH) after acute ischemic stroke (AIS). We sought to study the effect of DC on functional outcomes in patients with sICH after AIS who underwent mechanical thrombectomy (MT). METHODS: Patients with AIS from anterior circulation large vessel occlusion who underwent MT and subsequently developed sICH were identified from the Stroke Thrombectomy and Aneurysm Registry database. The primary outcome was acceptable 90-day functional neurological outcome, defined as modified Rankin scale (mRS) 0-3. Multivariable logistic regression and propensity-score matching were used to identify and quantify risk factors. RESULTS: Of 464 patients identified with sICH after AIS after MT, 97 patients (20.9%) underwent DC. Patients who underwent DC were more likely to be female ( P < .001), younger ( P < .001), have a measured medical comorbidity, have higher baseline mRS ( P = .02), and have higher-grade hemorrhages ( P = .01). At 90 days, 14% of patients had the primary outcome of mRS 0-3 and 56% had died. The primary outcome was observed in 11 patients who underwent DC (11%) and 55 (15%) of those without DC (odds ratio [OR] 0.7, 95% CI 0.4-1.4, P = .40). DC did not affect mRS shift at 90 days ( P = .10) but was associated with lower mortality (OR 0.5, 95% CI 0.3-0.8, P = .01). Multivariable analysis demonstrated that DC decreased the odds of primary outcome (adjusted OR 0.2, 95% CI 0.02-0.9, P = .045), but did not affect mortality ( P = .94), mRS shift ( P = .50), or length of stay ( P = .90). Propensity-matched analysis similarly demonstrated that non-DC patients were more likely to achieve the primary outcome (24% vs 8%, P = .045). CONCLUSION: In patients with sICH after AIS after MT, those selected for DC had less favorable outcomes and similar rates of mortality at 90 days.
Stereotactic radiosurgery versus observation for intracranial low-grade dural arteriovenous fistulas
Becerril‐Gaitan, Andrea , Peesh, Pedram , Liu, Collin, Lee, Cheng-chia, Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Hoang, A, Sheehan, Jason P. , Dayawansa, Sam , Samanci, Yavuz, Starke, Robert M. , Ikeda, Go , Kano, Hideyuki , Wang, Qian , Welch, Babu G. , O’Con, Jennifer, Lanzino, Guiseppe, Brinjikji, Waleed , Hayakawa, M. , Gross, Bradley A. , Albuquerque, Felipe C , Lawton, Michael T., Kim, Louis J. , Alaraj, Ali , Winkler, Ethan A. , Chalouhi, Nohra , Bulters, Diederik , Durnford, Andrew , Satomi, Junichiro, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Laurent, Dimitri , Bahmani, Brigette, Zipfel, Gregory J. , Samancı, Yavuz , Tripathi, Manjul , Welch, Babu , Du, Rose , Lai, Rosalind , Gross, Bradley , Levitt, Michael R , Alaraj, Ali , van DijK, J Marc C , Osbun, Joshua W , Bulters, Diederik O , Yang, Huai‐Che , Peker, Selçuk , Abdelsalam, Ahmed , Kondziolka, Douglas , Bernstein, Kenneth, Ming, Ying, Liščák, Roman , May, Jaromír , Li, Wen , O’Con, Jennifer, Amin-Hanjani, Sepideh , Nguyen, Quang, Samaniego, Edgar A , Lai, Pui Man Rosalind , Derdeyn, Colin P. , Abla, Adib A. , Lawton, Michael T. , Kim, Louis J. , Levitt, Michael R. , Hoh, Brian L. , Chen, Ching‐Jen

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | June 6, 2025 | Volume: 96 | Issue: 11 | Pages: 1117-1125

10.1136/jnnp-2024-335675 | PMID 40480804 Get It

Background Given the low haemorrhagic risk of intracranial low-grade dural arteriovenous fistulas (dAVFs), the benefits of routine intervention remain controversial. This study compares patient outcomes treated with stereotactic radiosurgery (SRS) versus conservative management. Method Multicentre retrospective analysis of the Consortium for Dural Arteriovenous Fistula Outcomes Research and the International Radiosurgery Research Foundation data. Inclusion criteria were (1) intracranial low-grade dAVF diagnosed by catheter-based angiography, (2) no prior dAVF-related haemorrhage and (3) management with upfront SRS (intervention group) or conservative management (observation group). The primary outcome was symptomatic improvement. Secondary outcomes included dAVF obliteration, up-conversion, haemorrhage, improvement and favourable modified Rankin Scale (mRS) at follow-up. Results 304 patients with a mean age of 56 years (SD 13.5) and a follow-up of 46.7 months (SD 45.5) were included. 135 (44.4%) were managed conservatively and 169 (55.6%) had upfront SRS. Compared with the observation group, symptomatic and mRS Score improvement (≥1-point decrease in baseline score) was more likely in the intervention group (95.1% vs 58.5%; OR=13.75 (5.61–33.69) and 37.0% vs 24.0%; OR=1.85 (1.09–3.15), respectively). These findings remained significant after multiple imputation and propensity score matching. Remaining outcomes were similar between groups. The all-cause mortality rate was 5.4% (n=16), unrelated to the dAVF or treatment. Five (3.0%) SRS-related complications were reported and resolved during the follow-up period. Conclusions SRS was associated with increased symptomatic and mRS Score improvement for low-grade dAVFs compared with conservative management. SRS had a low complication risk and did not appear to alter dAVF obliteration or haemorrhage. Future prospective trials on SRS as a first-line intervention for symptomatic low-grade dAVFs should be considered.
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
Élez, Elena , Shen, Lin , Kim, Tae Won, Yaeger, Rona , Usari, Tiziana, Laliberte, Robert J, Dychter, Samuel S., Zhang, Xiaosong , Yoshino, Takayuki , Lonardi, Sara , Cutsem, Eric Van , Eng, Cathy , Kim, Tae Won, Wasan, Harpreet , Desai, Jayesh , Ciardiello, Fortunato , Maughan, Tim , Morris, Van K. , Wu, Christina N. , Tabernero, Josep , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | June 4, 2025 | Volume: 43 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2025.43.17_suppl.lba3500 Get It

LBA3500 Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ± chemotherapy (chemo) vs standard of care (SOC; chemo ± bevacizumab) in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study previously met one of its dual primary endpoints (EPs) demonstrating clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) by blinded independent central review (BICR) in the ORR subset. These results were the basis for the FDA accelerated approval of EC+mFOLFOX6 for BRAF V600E-mutant mCRC, including in the 1L, under Project Frontrunner. Here, we report the primary analysis of progression-free survival (PFS) by BICR, updated interim analysis of OS, updated safety, and other analyses. Methods: Eligible patients (pts) with untreated BRAF V600E-mutant mCRC were randomized 1:1:1 to receive EC, EC+mFOLFOX6, or SOC; EC arm enrollment was closed after a protocol amendment. Dual primary EPs: ORR and PFS by BICR (EC+mFOLFOX6 vs SOC); key secondary EP: OS (EC+mFOLFOX6 vs SOC). Results: 637 pts were randomized to EC, EC+mFOLFOX6, or SOC. Baseline demographics and disease characteristics were generally balanced between arms. EC+mFOLFOX6 (data cutoff: Jan 6, 2025) demonstrated a clinically meaningful and statistically significant PFS improvement vs SOC, meeting the other dual primary EP; HR=0.53 (95% CI 0.407, 0.677; P<0.0001); median PFS 12.8 vs 7.1 mo. OS was clinically meaningful and statistically significant vs SOC; HR=0.49 (95% CI 0.375, 0.632; P<0.0001); median OS 30.3 vs 15.1 mo. Median PFS and OS in the EC arm were 6.8 and 19.5 mo. These data and response data for all randomized pts are shown in the table. Serious treatment-emergent adverse events occurred in 30%, 46%, and 39% of pts in the safety analysis set. Safety was consistent with that known for each agent. Conclusions: BREAKWATER demonstrated clinically meaningful and statistically significant PFS and OS improvements with EC+mFOLFOX6 vs SOC and manageable toxicities. EC+mFOLFOX6 is potentially practice changing as the new SOC. Clinical trial information: NCT04607421 . ECn=158 EC+mFOLFOX6n=236 SOCn=243 EC+mFOLFOX6vs SOCHR (95% CI)P-value a Median PFS b , mo (95% CI) 6.8(5.7, 8.3) 12.8(11.2, 15.9) 7.1(6.8, 8.5) 0.53 (0.407, 0.677) <0.0001 Median OS, mo (95% CI) 19.5(17.6, 22.5) 30.3(21.7, NE) 15.1(13.7, 17.7) 0.49 (0.375, 0.632)<0.0001 ORR, b % (95% CI) 45.6(38.0, 53.3) 65.7(59.4, 71.4) 37.4(31.6, 43.7) Median DOR b , mo (95% CI) c 7.0 (4.2, 11.6) 13.9 (10.9, 18.5) 10.8 (7.6, 13.4) DOR b ≥6 mo, n (%) c 29 (40.3) 110 (71.0) 38 (41.8) DOR b ≥12 mo, n (%) c 15 (20.8) 54 (34.8) 16 (17.6) Median time to response, b wk (range) c 6.6(4.3-86.4) 7.0(5.1-103.6) 7.3 (5.4-48.0) a 1-sided stratified log rank test. b By BICR. c Responders: n=72, n=155, and n=91. DOR, duration of response.
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Fletcher, Kylie , Menzies, Alexander M., Johnson, Alexandra , Olsson‐Brown, Anna , Carlino, Matteo S. , Malgeri, Andrea , Singh, Aditi P. , Naqash, Abdul Rafeh , Long, Georgina V. , Challa, Pavan, Johnson, Douglas B. , Kim, So Yeon , Singh, Aditi, Long, Georgina V , Naqash, Abdul Rafeh , Kim, So Yeon , Machaalani, Marc , Chehade, Razane El Hajj , Nassar, Amin H. , Nawfal, Rashad , Manos, Michael P. , Menzies, Alexander M , Nana, Frank Aboubakar , Hassel, Jessica Cecile , Pinato, David J. , Johnson, Alexandra, Cortellini, Alessio , Parikh, Kaushal , Kim, So Yeon , Choueiri, Toni K. , Sharon, Elad , Shah, Shailee

Mayo Clinic

JAMA Network Open | June 4, 2025 | Volume: 8 | Issue: 6 | Pages: e2513727

10.1001/jamanetworkopen.2025.13727 | PMID 40465294 Get It

Importance Immune checkpoint inhibitors (ICIs) are efficacious in many cancer types but can produce immune-related adverse events (irAEs). As such, patients with preexisting autoimmune disorders are often excluded from clinical trials, although subsequent studies have shown that many of these patients have acceptable ICI tolerance. The safety and efficacy of ICIs among patients with preexisting neurologic autoimmune disorders (NAIDs) is not well characterized. Objective To evaluate the safety and clinical outcomes associated with ICI therapy among patients with NAIDs. Design, Setting, and Participants This multicenter retrospective cohort study included patients with cancer who were treated with ICIs between October 2013 and May 2023 and had preexisting multiple sclerosis (MS), myasthenia gravis (MG), Guillain-Barré syndrome (GBS), and other NAIDs as well as a control cohort of patients with Parkinson disease (PD). Exposure ICI therapy. Main Outcomes and Measures Demographic and clinical characteristics (neurologic disability, active or recent immunosuppression), ICI outcomes (response, progression-free survival [PFS], and overall survival [OS]), and safety outcomes (NAID exacerbation, irAEs) were collected. Results A total of 135 patients were included; the median (range) age was 72 (40-88) years, 84 (62%) were men, and 51 (38%) were women. A total of 45 patients had MS; 18, MG; 10, GBS; 5, another NAID; and 57, PD. Exacerbations occurred most frequently in MG (12 of 18 patients [67%]), often resulting in hospitalization (6 [50%]) or death (2 [17%]), with much lower rates in the MS cohort (8 of 45 patients [18%]). Ten patients with a history of GBS tolerated ICI without exacerbations, although 1 developed a fatal case of Lambert Eaton myasthenic syndrome following ICI treatment. No differences in response rate, PFS, or OS were observed between NAID groups. Conclusions and Relevance In this cohort study of ICI use in NAIDs, patients with MG had frequent and more severe exacerbations, while those with MS had few exacerbations. No obvious differences in survival between groups were observed. ICI may be an option for many patients with appropriate oncologic indications and preexisting NAIDs.
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi, Shadi, Shu, Liqi , Mandel, Daniel , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Seiffge, David , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Mena, Diego López, Araúz, Antonio , Nehme, Ahmad , Boulanger, Marion , Sousa, João André , Sargento‐Freitas, João , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Kaufmann, Josefin E. , Engelter, Stefan T. , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Metanis, Issa , Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , MacDonald, Jason , Shahripour, Reza Bavarsad , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim, Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Giles, James , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Chulluncuy‐Rivas, Roberto, Aziz, Yasmin , Bakradze, Ekaterina , Tran, Thanh Lam , Rodrigo‐Gisbert, Marc , Velez, Faddi Saleh, Gracia, Jorge Ortiz, Mudassani, Varsha, Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Ranasinghe, Tamra , Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel, Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Lingam, Sivani, Quereshi, Abid, Alvarado, Alonso, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris, Vasilis, Martínez-Marino, Manuel , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Kala, Narendra , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Alvarado‐Bolaños, Alonso , Tentolouris-Piperas, Vasileios , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Liebeskind, David S. , Field, Thalia S , Keser, Zafer , Aziz, Yasmin , Mandel, Daniel M , Seiffge, David , Arauz, Antonio , Sousa, Joao Andre , Sargento-Freitas, Joao , Castro-Chaves, Paulo , Kaufman, Josefin E , Engelter, Stefan T , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Nolte, Christian H , Bavarsad Shahripour, Reza , Almajali, Mohammad , Fonseca, Ana Catarina , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Nzwalo, Hipolito , Mac Grory, Brian , Eltatawy, Ali , Rodrigo Gisbert, Marc , Vishnu, Venugopalan Y , Ranasinghe, Tamra , Mendes Ferreira, Vítor , Kim, Young Dae , Elangovan, Cheran , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Ghani, Mohammad , Xiao, Han , Khan, Farhan , Nehme, Ahmad , Yaghi, Shadi , Antonenko, Kateryna , Arnold, Marcel , Touzé, Emmanuel , Leker, Ronen R , Burton, Tina , von Rennenberg, Regina , MacDonald, Jason, Guo, Xiaofan , Samaniego, Edgar A , Rioux, Bastien , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Zedde, Marialuisa , Pascarella, Rosario , Anadani, Mohammad , Kicielinski, Kimberly , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Siegler, James E. , Willey, Joshua , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Martins, Sheila , Fridman, Sebastian , Liu, Shilin , Ali, Farman, Morsi, Rami Z. , Sokhi, Dilraj , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Stretz, Christoph , Goldstein, Eric

Mayo Clinic

Stroke | June 4, 2025 | Volume: 55 | Issue: 4 | Pages: 908-918

10.1161/strokeaha.123.045731 | PMID 38335240 Get It

BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Novel mouse model reveals neurodevelopmental origin of PMM2-CDG brain pathology
Edmondson, Andrew C. , Xia, Zijie , Melendez-Perez, Ashley, Cai, Cadmus, Collins, Ashley M., Shiplett, Emily J. , Hill, Sophie F. , Somarowthu, Ala , Dam, Jacques Van, Pai, Ling-Lin, Santi, Mariarita , He, Miao , Radenkovic, Silvia , Hill, Sophie F , Edmondson, Andrew C , Budhraja, Rohit , Xia, Zijie, Melendez-Perez, Ashley J. , Cai, Cadmus, Dam, Johanna, Kim, Seonhee , He, Miao, Goldberg, Ethan M. , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh , Zhou, Zhaolan

Mayo Clinic

No container title available | June 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.01.657261 | PMID 40501776 Get It

Abstract Congenital disorders of glycosylation (CDG) are a group of neurogenetic conditions resulting from disruptions in the cellular glycosylation machinery. The majority of CDG patients have compound heterozygous pathogenic variants in the phosphomannomutase 2 ( PMM2) gene. Individuals with PMM2-CDG exhibit multi-systemic symptoms, prominently featuring neurological deficits with nearly all patients exhibiting cerebellar hypoplasia and ataxia. To overcome embryonic lethality caused by whole body knock-out of Pmm2 and mimic patient-related compound heterozygous pathogenic variants, we paired a Pmm2 flox allele ( Pmm2 fl ) with a catalytically inactive knock-in allele ( Pmm2 R137H ), commonly present in PMM2-CDG patients. Mice with post-mitotic loss of PMM2 from neurons or astrocytes are indistinguishable from unaffected littermates, including in a broad battery of neurological assessments. In contrast, removal of PMM2 from embryonic neural precursor cells leads to cerebellar hypoplasia, ataxia, seizures, and early lethality. Comprehensive multi-omics profiling, including metabolomics, glycomics, single-cell transcriptomics, proteomics, and glycoproteomics, reveal widespread molecular disturbances throughout the brain, with the cerebellum showing the most pronounced disruption. These findings highlight the heightened dependency of the developing cerebellum on intact N-glycosylation, aligning with clinical observations in PMM2-CDG patients. Importantly, glycoproteomic alterations identified in our mouse model are corroborated in PMM2-CDG patient post-mortem cerebellar tissue, underscoring the translational relevance of our findings and implicating impaired synaptic transmission as a key pathogenic mechanism.
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
Danpanichkul, Pojsakorn , Thongprayoon, Charat, Suparan, Kanokphong , Kim, Donghee , Wanichthanaolan, Ornpailin , Pang, Yanfang , Kulkarni, Anand V. , Yang, Ju Dong , Cheungpasitporn, Wisit, Cheungpasitporn, Wisit , Kulkarni, Anand V , Yang, Ju Dong , Kaewdech, Apichat , Wijarnpreecha, Karn , Cheungpasitporn, Wisit , Kim, Donghee , Danpanichkul, Pojsakorn , Thongprayoon, Charat , Wattanachayakul, Phuuwadith , Pang, Yanfang , Muthiah, Mark D , Kaewdech, Apichat , Wijarnpreecha, Karn

Mayo Clinic

Journal of Gastroenterology and Hepatology | June 4, 2025 | Volume: 40 | Issue: 8 | Pages: 2053-2059

10.1111/jgh.17009 | PMID 40462409 Get It

ABSTRACTBackgroundMetabolic dysfunction‐associated steatotic liver disease (MASLD) affects over one third of the global population and is closely linked to gastrointestinal, oncological, and cardiovascular diseases. As the most common cause of steatotic liver disease (SLD), MASLD is often referred to as “fatty liver” in general health information searches. With the Internet becoming a primary source of healthcare information, this study aimed to evaluate global and regional public interest in steatotic liver disease using Google Trends data from January 2004 to December 2024.MethodsA comprehensive analysis was performed using Google Trends with the search term “fatty liver disease.” Interest levels were quantified using Google Trends indices, and temporal patterns were evaluated using average annual percent change (AAPC). Regional variations were assessed to identify geographic hotspots of public interest.ResultsGlobal interest in MASLD demonstrated significant growth (AAPC: 6.77%, 95% Confidence interval [CI]: 5.33–8.23), with a 264% increase from 2004 to 2024. Peak interest was observed in August 2024 (index: 100) compared to the lowest point in June 2007. Iran showed the highest country‐specific search volume (index: 100), while within the United States, West Virginia demonstrated the greatest relative interest (index: 100). Key topics associated with MASLD included “liver,” “symptoms,” “disease,” and “therapy.”ConclusionsSubstantial growth in global public interest in MASLD, with distinct temporal and geographical patterns, provides insights to develop targeted awareness campaigns and educational interventions, particularly in regions with low search volumes. Future research should examine the relationship between online search patterns and clinical outcomes in MASLD.
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, Gary R. , Afzali, Anita , Long, Millie D. , Ha, Christina , Ha, Christina Y, Loftus, Edward V. , Barnes, Edward L. , Isaacs, Kim L.

Mayo Clinic

American Journal of Gastroenterology | June 3, 2025 | Volume: 120 | Issue: 6 | Pages: 1225-1264

10.14309/ajg.0000000000003465 | PMID 40701562 Get It

Crohn's disease (CD) is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of CD has steadily increased over the past several decades. The diagnosis and treatment of patients with CD has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology and were developed under the auspices of the Practice Parameters Committee for the management of adult patients with CD. These guidelines are established for clinical practice with the intent of suggesting preferable approaches to medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When exercising clinical judgment, health care providers should incorporate this guideline along with patient's needs, desires, and their values to care for patients fully and appropriately with CD. Shared decision-making with the patient is advocated. This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. To evaluate the level of evidence and strength of recommendations, we used the Grading of Recommendations Assessment, Development, and Evaluation system. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fields. The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments later.